Compare MQ & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | STOK |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2021 | 2019 |
| Metric | MQ | STOK |
|---|---|---|
| Price | $3.87 | $31.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $5.36 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 5.1M | 475.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,884,000.00 | $184,420,000.00 |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $16.36 | $77.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 23.25 | ★ 404.50 |
| 52 Week Low | $3.70 | $11.17 |
| 52 Week High | $7.04 | $40.22 |
| Indicator | MQ | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 53.24 |
| Support Level | $3.81 | $30.34 |
| Resistance Level | $4.26 | $35.11 |
| Average True Range (ATR) | 0.18 | 1.46 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 30.47 | 86.66 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.